Geoffrey I Shapiro

Geoffrey I Shapiro

UNVERIFIED PROFILE

Are you Geoffrey I Shapiro?   Register this Author

Register author
Geoffrey I Shapiro

Geoffrey I Shapiro

Publications by authors named "Geoffrey I Shapiro"

Are you Geoffrey I Shapiro?   Register this Author

100Publications

3640Reads

48Profile Views

Functional profiling of nucleotide Excision repair in breast cancer.

DNA Repair (Amst) 2019 Aug 30;82:102697. Epub 2019 Aug 30.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dnarep.2019.102697DOI Listing
August 2019

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance.

Cell Rep 2019 Mar;26(10):2667-2680.e7

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.02.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449498PMC
March 2019

Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?

Stem Cell Investig 2019 22;6. Epub 2019 Feb 22.

Breast Oncology Program and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://sci.amegroups.com/article/view/24095/html
Publisher Site
http://dx.doi.org/10.21037/sci.2019.02.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414355PMC
February 2019

Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search.

Cancer Cell 2017 12;32(6):721-723

Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.11.013DOI Listing
December 2017

Synergy of WEE1 and mTOR Inhibition in Mutant -Driven Lung Cancers.

Clin Cancer Res 2017 Nov 18;23(22):6993-7005. Epub 2017 Aug 18.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-1098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690829PMC
November 2017

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.

Eur J Cancer 2017 11 20;86:296-304. Epub 2017 Oct 20.

Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.09.011DOI Listing
November 2017

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.

Invest New Drugs 2017 04 23;35(2):189-197. Epub 2017 Jan 23.

University of Pittsburgh Cancer Institute/UPMC, 5150 Centre Avenue, Fifth Floor, Pittsburgh, PA, 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0409-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352756PMC
April 2017

The evolving role of cyclin-dependent kinase inhibitors in cancer management.

Clin Adv Hematol Oncol 2017 Mar;15(3):174-177

Early Drug Development Center, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
March 2017

Sensitizing HR-proficient cancers to PARP inhibitors.

Mol Cell Oncol 2017 3;4(6):e1299272. Epub 2017 Mar 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23723556.2017.1299272DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706951PMC
March 2017

A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.

Invest New Drugs 2017 02 16;35(1):68-78. Epub 2016 Nov 16.

University of California - San Francisco, Box 1705, UCSF, San Francisco, CA, 94143-1705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0399-7DOI Listing
February 2017

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.

Br J Cancer 2017 Feb 19;116(4):432-440. Epub 2017 Jan 19.

Department of Medical Oncology, Dana-Farber Cancer Institute, Early Drug Development Center, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.419DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318966PMC
February 2017

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

J Clin Oncol 2017 Jan 21;35(2):157-165. Epub 2016 Nov 21.

Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.2048DOI Listing
January 2017

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 12 31;34(36):4371-4380. Epub 2016 Oct 31.

Suzanne Leijen, Robin M.J.M. van Geel, and Jan H.M. Schellens, The Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands; Anna C. Pavlick, New York University Medical Center, New York, NY; Lee Rosen, University of California Los Angeles, Santa Monica, CA; Raymond Lam, Shelonitda Rose, Mark A. Lee, Tomoko Freshwater, and Stuart Shumway, Merck, Kenilworth, NJ; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Albiruni R. Abdul Razak and Amit M. Oza, Princess Margaret Hospital, Toronto, Ontario, Canada; Raoul Tibes, University Hospital of Würzburg, Würzburg; Tim Demuth, Sandoz AG, Holzkirchen, Germany; and Li Wen Liang, Merck Sharp & Dohme R&D, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.5991DOI Listing
December 2016

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.

Breast Cancer Res Treat 2016 11 6;160(2):305-312. Epub 2016 Oct 6.

Department of Medical Oncology, Breast Oncology Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-4001-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065609PMC
November 2016

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.

Breast Care (Basel) 2016 Jun 22;11(3):167-73. Epub 2016 Jun 22.

Breast Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA, MA, USA; Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000447284DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960359PMC
June 2016

Targeting CDK4 and CDK6: From Discovery to Therapy.

Cancer Discov 2016 Apr 11;6(4):353-67. Epub 2015 Dec 11.

Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/content/early/2015/1
Web Search
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-15-0894DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821753PMC
April 2016

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

Cancer Discov 2015 Nov 13;5(11):1137-54. Epub 2015 Oct 13.

Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-0714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631624PMC
November 2015

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

N Engl J Med 2015 Jul;373(5):428-37

From Memorial Sloan Kettering Cancer Center (W.D.T., J.H.H.) and Weill Cornell Medical College (W.D.T.) - both in New York; University of California, Los Angeles, Medical Center, Los Angeles (Z.A.W., B.C., A.S.S.), Plexxikon, Berkeley (P.N.I., C.Z., J.Z., G.H., Y.Z., E.A.B., G.V., L.S., P.S., H.N., M.J.K., A.M., G.T., R.S., C.G., B.L.W., P.H., K.N., H.H.H., P.S.L., S.T.-S., G.B.), and Stanford University School of Medicine, Stanford (M.R.) - all in California; Evergreen Hematology and Oncology, Spokane, WA (S.P.A.); University of Pennsylvania School of Medicine, Philadelphia (A.P.S.); Rocky Mountain Cancer Centers, Denver (A.L.C.); Dana-Farber Cancer Institute (G.I.S., A.J.W.) and Massachusetts General Hospital (E.L.K.) - both in Boston; Vanderbilt University Medical Center, Nashville (V.L.K., I.P.); Virginia G. Piper Cancer Center at Scottsdale Healthcare-Translational Genomics Research Institute (TGen), Scottsdale, AZ (D.D.V.H., G.J.W., R.K.R.); and Spire Sciences, Boca Raton, FL (C.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411366DOI Listing
July 2015

A phase 1 study of ABT-806 in subjects with advanced solid tumors.

Invest New Drugs 2015 Jun 17;33(3):671-8. Epub 2015 Apr 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0234-6DOI Listing
June 2015

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).

Cancer Immunol Immunother 2015 Apr 13;64(4):437-46. Epub 2015 Jan 13.

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, MSK 60th Street Outpatient Center, Suite 302, New York, NY, 10065, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-015-1653-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6730642PMC
April 2015

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

Clin Cancer Res 2015 Feb 5;21(4):925-33. Epub 2014 Dec 5.

Northern Institute for Cancer Research, Framlington Place, The Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom. Hepatopancreatobiliary Team, The Freeman Hospital, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0842DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335075PMC
February 2015

The biology and clinical development of MEK inhibitors for cancer.

Drugs 2014 Dec;74(18):2111-28

Melanoma and Developmental Therapeutics Clinics, University of Chicago Cancer Center, University of Chicago, 5841 S. Maryland Ave., MC2115, Chicago, IL, 60637, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-014-0315-4DOI Listing
December 2014

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Nov 27;371(21):1963-71. Epub 2014 Sep 27.

From the Massachusetts General Hospital Cancer Center (A.T.S., L.P.L., Z.Z., J.W.C., A.J.I.), Dana-Farber Cancer Institute (G.I.S.), and Beth Israel Deaconess Medical Center (D.B.C.) - all in Boston; University of California at Irvine, Irvine (S.-H.I.O.), and Pfizer Oncology, La Jolla (W.T., S.M.S., L.M.T., J.G.C., K.D.W.) - both in California; Seoul National University Hospital, Seoul, South Korea (Y.-J.B.); University of Colorado, Aurora (D.R.C., M.V.-G., R.C.D.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); University of Chicago, Chicago (R.S.); Memorial Sloan Kettering Cancer Center, New York (G.J.R.); Karolinska Institutet, Stockholm (Z.Z.); and Rho, Chapel Hill, NC (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1406766DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264527PMC
November 2014

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.

J Natl Cancer Inst 2014 Jul 24;106(7). Epub 2014 Jun 24.

Affiliations of authors: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA (SED); Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (GIS, BEJ); Department of Hematology and Oncology (JWC) and Department of Medicine (JWC), Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju163DOI Listing
July 2014

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Cancer Discov 2014 May 13;4(5):546-53. Epub 2014 Mar 13.

Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, 3Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of 4Medicine and 5Pathology, Brigham and Women's Hospital, Harvard Medical School; 6Division of Hematology/Oncology, Massachusetts General Hospital, Boston; 7Broad Institute of Harvard and MIT; 8Department of Biology, Whitehead Institute for Biomedical Research; 9Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts; and 10Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122326PMC
May 2014

Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.

J Thorac Oncol 2014 Mar;9(3):316-23

*Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts; †Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; ‡Translational Medicine, Exelixis, Inc., South San Francisco, San Francisco, California; §Translational and Experimental Medicine, Sanofi, Vitry-sur-Seine, France; ‖Center for Thoracic Centers, Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts; ¶Clinical Development Oncology, Sanofi, Cambridge, Massachusetts; #Pharmacokinetic Modeling and Simulation, Sanofi, Cambridge, Massachusetts; **Biostatistics and Programming, Sanofi, Cambridge, Massachusetts; ††Early Drug Development Center, Dana-Farber Cancer Institute, Boston, Massachusetts; ‡‡Department of Medical Oncology, Vall d'ebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153021
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000088DOI Listing
March 2014

Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.

J Natl Compr Canc Netw 2014 Mar;12(3):323-6; quiz 326

From aDana-Farber Cancer Institute, Harvard Medical School and bBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; cUniversity of Rochester Medical Center, University of Rochester, Rochester, New York; and dMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0034DOI Listing
March 2014

Aurora kinase inhibition as an anticancer strategy.

J Clin Oncol 2014 Jan 16;32(1):57-9. Epub 2013 Sep 16.

Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.7988DOI Listing
January 2014

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.

Clin Cancer Res 2014 Jan 28;20(1):233-45. Epub 2013 Oct 28.

Authors' Affiliations: Dana-Farber Cancer Institute; Massachusetts General Hospital; Beth Israel Deaconess Medical Center, Boston, Massachusetts; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Mary Crowley Cancer Research Centers, Dallas, Texas; Exelixis Inc., South San Francisco, California; and Sanofi, Cambridge, Massachusetts, and Vitry-sur-Seine, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1777DOI Listing
January 2014

Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.

Clin Cancer Res 2014 Jan 30;20(2):413-24. Epub 2013 Oct 30.

Authors' Affiliations: Synta Pharmaceuticals Corp., Lexington; Early Drug Development Center, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, Massachusetts; and Department of Medicine, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2166DOI Listing
January 2014

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

J Clin Oncol 2014 Jan 9;32(2):68-75. Epub 2013 Dec 9.

Leena Gandhi, Sara M. Tolaney, James M. Cleary, and Geoffrey I. Shapiro, Dana-Farber Cancer Institute; Eunice L. Kwak, Massachusetts General Hospital; Shuchi S. Pandya, Beth Israel Deaconess Medical Center, Boston; Anna Berkenblit and Mizue Krygowski, Aveo Pharmaceuticals; Revathi Ananthakrishnan and Kathleen W. Turnbull, Inventiv Health, Cambridge, MA; Rastislav Bahleda, Antoine Hollebecque, and Jean-Charles Soria, Insitut Gussav Roussy, Villejuif, France; Richat Abbas and Yali Liang, Pfizer, Collegeville, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.47.2787
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.47.2787DOI Listing
January 2014

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Cancer Discov 2013 Dec 27;3(12):1355-63. Epub 2013 Sep 27.

Departments of 1Medicine and 2Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Ludwig Institute for Cancer Research; 5Department of Neurosurgery, Massachusetts General Hospital; 6Belfer Institute for Applied Cancer Science; 7Department of Pathology, Brigham and Women's Hospital, Boston; 8Broad Institute, Cambridge, Massachusetts; 9UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and 10Department of Molecular Pharmacology and Therapeutics, Oncology Institute, Loyola University, Chicago, Illinois; 11Department of Physiology, University of Valencia, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864135PMC
December 2013

NUT midline carcinoma: an aggressive intrathoracic neoplasm.

J Thorac Oncol 2013 Oct;8(10):1335-8

*Department of Oncology, Mayo Clinic, Rochester, Minnesota; †Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; ‡Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; §GlaxoSmithKline, Philadelphia, Pennsylvania; and ‖Early Drug Development Center, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a00f41DOI Listing
October 2013

Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.

Cancer 2013 Aug 14;119(16):3043-51. Epub 2013 Jun 14.

Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28120DOI Listing
August 2013

Poly(ADP-ribose) polymerase inhibitors as cancer therapy.

Front Biosci (Landmark Ed) 2013 Jun 1;18:1392-406. Epub 2013 Jun 1.

Early Drug Development Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/16/19/4702.ful
Web Search
June 2013

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

Invest New Drugs 2013 Apr 2;31(2):370-80. Epub 2012 Jun 2.

Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-012-9825-7DOI Listing
April 2013

Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.

Future Oncol 2013 Feb;9(2):271-81

Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC 20007, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.12.195DOI Listing
February 2013

Cyclin-dependent kinase 4/6 inhibition in cancer therapy.

Cell Cycle 2012 Nov 3;11(21):3913. Epub 2012 Oct 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.22390DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507481PMC
November 2012